OBJECTIVES: Upon completion of this activity, the participant should be able to:

1. Identify SGLT2i and GLP1 agonist drugs

2. Identify adverse effect risks and necessity of cessation timing of these classes of drugs preoperatively

3. Recognize perioperative management of patients on SGLT2i and GLP1 agonists

FACULTY DISCLOSURE: John Cargile, MD has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Amy Sanders. Amy.Sanders@BSWHealth.org

 

 

Session date: 
02/01/2024 - 6:45am to 7:45am CST
Location: 
Temple, TX
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
    The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • 1.00 Attendance

Please login or register for this course.